BioLineRx Ltd.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BioLineRx Ltd. develops and commercializes therapies for oncology and other critical diseases.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-14 16:01 |
Earnings Release
Second Quarter 2025 Financial Results and Provides Corporate Update
|
English | 375.7 KB | |
| 2025-08-14 16:01 |
Foreign Filer Report
Second Quarter 2025 Financial Results and Provides Corporate Update
|
English | 36.5 KB | |
| 2025-07-26 23:19 |
Prospectus
Immediate Report
|
English | 397.4 KB | |
| 2025-07-26 23:19 |
Prospectus
Immediate Report
|
English | 36.3 KB | |
| 2025-07-01 01:25 |
Foreign Filer Report
Immediate Report
|
English | 127.3 KB | |
| 2025-07-01 01:25 |
Foreign Filer Report
Immediate Report
|
English | 36.5 KB | |
| 2025-05-30 17:23 |
Foreign Filer Report
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-L…
|
English | 153.1 KB | |
| 2025-05-30 17:23 |
Foreign Filer Report
New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-L…
|
English | 36.4 KB | |
| 2025-05-27 16:01 |
Foreign Filer Report
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate U…
|
English | 430.8 KB | |
| 2025-05-27 16:01 |
Foreign Filer Report
BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate U…
|
English | 36.4 KB | |
| 2025-05-24 23:14 |
Proxy Solicitation & Information Statement
Immediate Report of Meeting to be held on June 29,2025,proxy statement
|
English | 160.1 KB | |
| 2025-05-24 23:14 |
Foreign Filer Report
Immediate Report of Meeting to be held on June 29,2025,proxy statement
|
English | 534.4 KB | |
| 2025-05-24 23:14 |
Pre-Annual General Meeting Information
Immediate Report of Meeting to be held on June 29,2025,proxy statement
|
English | 100.8 KB | |
| 2025-04-14 13:22 |
Prospectus
PROSPECTUS SUPPLEMENT
|
English | 415.1 KB | |
| 2025-04-14 13:22 |
Prospectus
PROSPECTUS SUPPLEMENT
|
English | 36.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Herantis Pharma Oyj | Finland | HRTIS | |
| Hiron-Trade Investments & Industrial Buildings Ltd. | Israel | HRON | ||
|
Human Stem Cells Institute PJSC | Russian Federation | ISKJ | |
|
Human Xtensions Ltd. | Israel | HUMX | |
|
Hybrigenics SA | France | ALHYG | |
|
Hyloris Pharmaceuticals SA | Belgium | HYL | |
|
Ikonisys S.A. | France | ALIKO | |
|
IMCB PJSC | Russian Federation | GEMA | |
|
Immunic AG | United States of America | IMUX | |
| Incanthera plc | United Kingdom | N/A |